Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 19, 2023 04:00 ET | Source: Oxford BioTherapeutics

Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim’s Upcoming Transforming Science Day: Europe

The panel discussion will highlight OBT’s successful 10-year partnership with Boehringer Ingelheim and the foundations it has been built on Oxford, UK, San Jose, Calif., 19th September 2023 -...
May 25, 2023 04:00 ET | Source: Oxford BioTherapeutics

Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
April 19, 2023 04:00 ET | Source: Oxford BioTherapeutics

Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck

Trial will investigate OBT076 as monotherapy and in sequence with balstilimabCD205, OBT076’s target antigen, is overexpressed in ~ 80 % of ACC tumor biopsy samplesRecurrent or metastatic ACC patients...
November 17, 2020 11:00 ET | Source: Deem

Deem Announces Leadership Changes

Oakland, CA, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Deem, a leading mobile and cloud technology provider for the corporate travel industry and a wholly owned and independently operated subsidiary of...